Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

MPP Inks Deals With 27 Generics Makers to Produce Merck’s COVID-19 Pill
MPP Inks Deals With 27 Generics Makers to Produce Merck’s COVID-19 Pill
The United Nations-backed Medicines Patent Pool (MPP) has secured agreements with 27 generics makers in Asia and Africa to supply Merck’s COVID-19 oral antiviral, molnupiravir, in 105 low- and mi...
Prospective of graphene and graphene-based derivatives to combat SARS-CoV-2 infection
Prospective of graphene and graphene-based derivatives to combat SARS-CoV-2 infection
In a study published in the latest issue of the journal Materials Today Advances, a team of researchers explored the utilities of graphene (GO) and its derivatives in combating the severe acute res...
Biotech Billionaire Launches Large Vaccine Manufacturing Plant in South Africa
Biotech Billionaire Launches Large Vaccine Manufacturing Plant in South Africa
Patrick Soon-Shiong, South African-born head of biotech firms NantWorks and ImmunityBio, has launched a new manufacturing facility in South Africa with the goal of producing 1 billion COVID-19 vacc...
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company i...
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gast...
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
Antares Pharma, Inc. (NASDAQ: ATRS), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATRS-1902 for adrena...
Celcuity Shares Rise 6% After Fast-Track Designation for Gedatolisib
Celcuity Shares Rise 6% After Fast-Track Designation for Gedatolisib
Celcuity Inc. shares were up 6% to $12.18 after the company said the U.S. Food and Drug Administration has granted Fast Track designation to the Company's lead drug candidate, gedatolisib, for the ...
Sarepta, Lysogene End Gene Therapy Pact for Rare Inherited Disorder
Sarepta, Lysogene End Gene Therapy Pact for Rare Inherited Disorder
Lysogene has ended its licensing deal with Sarepta Therapeutics for its LYS-SAF302, an experimental therapy for treating a rare inherited disease of the central nervous system called mucopolysaccha...
EMA Launches Review of Liver Disease Drugs Containing Terlipressin
EMA Launches Review of Liver Disease Drugs Containing Terlipressin
The European Medicines Agency’s (EMA) product safety committee has begun reviewing drugs treating an advanced liver disease that contain the active compound terlipressin. ...
Takeda’s and Denali’s Alzheimer’s Drug Hit With Clinical Hold
Takeda’s and Denali’s Alzheimer’s Drug Hit With Clinical Hold

The FDA has placed a clinical hold on Denali Therapeutics’ and Takeda Pharmaceutical’s experimental Alzheimer’s drug DNL919.

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigati...
Dementia: Popular sandwich could increase the risk of brain disease by 44 percent
Dementia: Popular sandwich could increase the risk of brain disease by 44 percent

DEMENTIA takes away a person's memories and personality, which can be devastating for loved ones to watch. 

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand